InvestorsHub Logo

H2R

Followers 42
Posts 2157
Boards Moderated 0
Alias Born 07/17/2014

H2R

Re: None

Tuesday, 11/05/2019 5:49:44 PM

Tuesday, November 05, 2019 5:49:44 PM

Post# of 196
Q3 2019: $36.8M v. $14.2 M Q3 2018!

This includes $35.7 million in net product revenues from sales of Andexxa/Ondexxya [coagulation factor Xa (recombinant), inactivated-zhzo], $17,000 in revenues from Bevyxxa® (betrixaban) sales and $1.1 million in collaboration and license revenues.